Physician profile
Michael Eng
NPI 1053882076
$6,514.55
in general payments reported to CMS, 2019-2025
47 companies · $3,406 in 2025
The $3,406 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.45 · 2024: $3,090 · 2025: $3,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,318.16 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $541.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $482.80 | 2024-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $421.76 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $360.48 | 2024-2025 | |
| Incyte Corporation | $329.91 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $322.18 | 2024-2025 | Enhertu |
| Gilead Sciences, INC. | $304.76 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $287.41 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Janssen Biotech, INC. | $259.03 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Stemline Therapeutics INC. | $229.43 | 2024-2025 | Orserdu, Elzonris |
| Puma Biotechnology, INC. | $214.10 | 2024-2025 | |
| Genzyme Corporation | $199.59 | 2024-2025 | |
| Lilly USA, LLC | $182.55 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $178.91 | 2024-2025 | |
| Genentech USA, INC. | $168.83 | 2021-2025 | Tecentriq, Tecentriq Hybreza, Phesgo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.